Transcatheter aortic valve implantation (TAVI) shows early superiority over surgical aortic valve replacement (SAVR) in preventing death or stroke, especially in high-risk patients.
This benefit attenuates over the long term, with no statistically significant difference observed at 5-year follow-up across low, intermediate, and high-risk groups.
Risk profile strongly influences event rates, with high-risk patients experiencing greater absolute benefits from TAVI over time.
